Ticlopidine hydrochloride NEW
| Price | $30 |
| Package | 1mL |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Ticlopidine hydrochloride | CAS No.: 53885-35-1 |
| Purity: 99.98% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Ticlopidine hydrochloride |
| Description | Ticlopidine hydrochloride (Ticlodix) is an effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES. |
| In vitro | Oral administration of Ticlopidine HCl in rats enhances the affinity of cyclase on platelet membranes for prostaglandin E1, subsequently activating both the basal and prostaglandin E1-stimulated without affecting the enzyme activity induced by adenosine or sodium fluoride. Ticlopidine HCl exhibits an inhibitory effect on platelet aggregation with an IC50 of 2 μM in males. |
| In vivo | Ticlopidine HCl inhibits platelet aggregation by activating basal PGE1-induced cyclase activity, blocking the enhancement of cyclase activity induced by PGE2, thereby increasing platelet c-AMP levels, and suppressing prostaglandin synthesis from endogenous substrates. Additionally, it alters platelet membrane function and inhibits aggregation through the blockade of ADP receptors. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 30 mg/mL (100 mM) DMSO : 65 mg/mL (216.49 mM), Sonication is recommended. |
| Keywords | Ticlopidine Hydrochloride | Inhibitor | P1 receptor | inhibit | Ticlopidine hydrochloride | Adenosine Receptor | Ticlopidine |
| Inhibitors Related | Theophylline monohydrate | Diphylline | Acefylline | Aminophylline | Inosine | Theobromine | Istradefylline | Theophylline | Adenosine antagonist-1 | Doxofylline |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $30.00/1mL |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $10.00/1KG |
VIP6Y
|
Hebei Weibang Biotechnology Co., Ltd
|
2024-10-31 | |
| $0.00/1KG |
VIP4Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2024-08-20 | |
| $6.00/1KG |
VIP2Y
|
Henan Fengda Chemical Co., Ltd
|
2024-01-24 | |
| $0.00/25KG |
VIP5Y
|
Hebei Mojin Biotechnology Co., Ltd
|
2023-09-06 | |
| $0.00/25kg |
Zhejiang Hengkang Pharmaceutical Co., Ltd.
|
2022-09-02 | ||
| $1.00/1kg |
Wuhan Dujiang Industrial Co., Ltd.
|
2022-02-15 | ||
| $0.00/1Kg/Bag |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2021-09-22 | |
| $15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-08-11 | ||
| $1.10/1g |
VIP4Y
|
Dideu Industries Group Limited
|
2021-08-04 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY